Discovery on Target
Discovery on Target Mobile Header

Cardio-Metabolic Drug Targets  



Cardiovascular disease, diabetes, obesity and dyslipidemia, though traditionally treated as separate entities, are often conditions that appear together in individuals because of defects in underlying metabolic processes. Researchers are therefore now seeking compounds that target biological points of intersection of these related diseases in the hopes of 'killing more birds with one stone.' Or they are approaching drug development of a compound for a specific disease with a greater awareness of the backdrop of related conditions.

Join fellow biomedical researchers from academia and industry at our day and a half conference, Cardio-Metabolic Drug Targets to discuss the impact of this paradigm change in the way drugs are discovered and developed in the cardio-metabolic arena and to stay abreast of the latest targets and drug development candidates in the pipeline.



September 23: Allosteric Modulators of GPCRs Short Course 4  

September 24 - 25: Novel Strategies for Kinase Inhibitors Conference  

September 25: Setting Up Effective Functional Screens Using 3D Cell Cultures Dinner Short Course  

September 25 - 26: Cardio-Metabolic Drug Targets Conference 

Scientific Advisory Board:

Jerome J. Schentag, Pharm.D., Professor of Pharmaceutical Sciences, University at Buffalo

Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals


Day 1 | Day 2 | Download Brochure | Download Track Brochure 


Wednesday, September 25

11:50 am Registration

1:30 pm Chairperson’s Opening Remarks


1:40 Plenary Keynote Speakers

Stuart L. Schreiber
Towards a Patient-Based Drug Discovery  

Stuart L. Schreiber, Ph.D., Director, Chemical Biology, Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical Institute Investigator; Morris Loeb Professor of Chemistry and Chemical Biology, Harvard University

 Paul L. Feldman
Enteroendocrine Drug Discovery for Treatment of Metabolic Diseases

Paul L. Feldman, Ph.D., Senior Vice President, GlaxoSmithKline


(also panelist in 'Cardio-Metabolic' track, day 2, 2:30pm 'Challenges in Diabetes and Atherosclerosis Drug Development') 

For complete Keynote details, click here 


3:10 Refreshment Break in the Exhibit Hall with Poster Viewing


3:50 pm Chairperson’s Opening Remarks
Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals 

4:00 FEATURED SPEAKER: Atherosclerosis and Cardio-Metabolism Research Overview: Promising Targets

Margrit SchwarzMargrit Schwarz, Ph.D., MBA, President, MS Consulting, LLC; formerly Director of Research, Dyslipidemia and Atherosclerosis, Amgen

Dyslipidemia as a risk factor for cardiovascular disease (CVD) is being effectively treated with statins, though residual CVD risk in most patients has prompted the development of new therapies. PCSK9 inhibitors have emerged as a new class of LDL-C lowering drugs with promising efficacy in clinical trials. Will they effectively address residual CVD risk, or is there a need for additional therapies that target atherosclerosis more directly? Drug discovery strategies beyond PCSK9 are being discussed.

Global Genomics Group4:30 Combining Next-Generation Phenotyping with Panomics – A New Standard for Biomarker and Drug Discovery

Szilard Voros, M.D., Founder & CEO, Global Genomics Group LLC

We present a comprehensive and integrated approach for biomarker and target discovery that addresses the shortcomings of current approaches to investigate disease-relevant pathways. By combining next-generation phenotyping through the use of advanced imaging with panomics, we investigate and analyze comprehensive, multidimensional biological networks. Our current focus is atherosclerosis in cardiovascular diseases.

5:00 Novel Treatment for Dyslipidemia: Liver-Directed Thyroid Hormone Receptor-ß Agonist

Rebecca TaubRebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals

Insulin resistant type 2 diabetics have a high incidence of atherosclerosis, and 65-80% of diabetics die of cardiovascular (CV) disease such as heart attacks and strokes.  Diabetes is associated with a dyslipidemia characterized by fatty liver, elevated triglycerides
(TGs), atherogenic LDL particles and low HDL cholesterol. MGL-3196, a liver-targeted THR beta agonist has a unique profile including insulin sensitization, reduction of cholesterol, triglycerides and liver triglycerides in animal models and reduction in LDL cholesterol (30%), triglycerides (60%) in human studies. MGL-3196 may be highly effective treatment for diabetic dyslipidemia that can reduce CV risk in type-2-diabetics.

5:30 Modulating Glycerolipid Metabolism in Myeloid Cells for Cardiometabolic Benefit

Suneil K. Koliwad, MD., Ph.D. Assistant Professor, Diabetes Center/Department of Medicine, University of California San Francisco (UCSF)

Intestinal DGAT enzymes have been targeted to lower body weight and reduce the progression of metabolic syndrome. Unfortunately, DGAT inhibition is associated thus far with several unwanted side effects. We have used these targets to uncover a link between glycerolipid flux within myeloid cell types (macrophages, dendritic cells, microglia) and inflammatory responsiveness. The work from our group has focused on DGAT enzymes as tools to modulate the flux of fatty acids within innate immune cells that are activated in metabolic tissues in the face of diet-induced obesity.

6:00  Targeting PCSK9 for Hypercholesterolemia and Atherosclerosis

Hong Liang, Ph.D., Associate Research Fellow, Rinat Research Unit, Pfizer

PCSK9 promotes LDLR degradation and increases serum LDL-C. We show that a humanized mAb (J16) potently and selectively reduces LDL-C in cynomolgus monkeys and humans. This effect is additive to that of the HMG-CoA reductase inhibitor. Furthermore, we show that a Mab engineered to have pH-sensitive binding to PCSK9 (J17) minimizes PCSK9-mediated degradation leading to extension in antibody half-life and prolonged duration of efficacy.

6:30 Close of Day

Day 1 | Day 2 | Download Brochure | Download Track Brochure